NCT02776033 is a Phase 2 clinical trial of GSK2982772 in Psoriasis, sponsored by GlaxoSmithKline.

Who is sponsoring NCT02776033?

NCT02776033 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT02776033?

Interventions in NCT02776033: GSK2982772, Placebo.

Is NCT02776033 still recruiting?

NCT02776033 is currently completed. Last updated 8 July 2020.

Are results published for NCT02776033?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-07-08 · How we verify

NCT02776033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis

Completed Phase 2 Results posted Last updated 8 July 2020

What this trial tests

Phase 2 trial testing GSK2982772 in Psoriasis in 65 participants. Completed in 4 January 2018.

Timeline

30 August 2016

Primary endpoint
4 January 2018

4 January 2018

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	65
Start date	30 August 2016
Primary completion	4 January 2018
Estimated completion	4 January 2018
Sites	4 locations across Canada

Drugs / interventions tested

GSK2982772 — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 75, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs Primary · Up to Day 116

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment. Safety Popul

Any SAE

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	1
GSK2982772 60 mg TID	1

Any non-SAE

Group	Value	95% CI
Placebo	8
GSK2982772 60 mg BID	21
GSK2982772 60 mg TID	16

Number of Participants With Worst-case Post-Baseline Clinical Chemistry Results by Potential Clinical Importance (PCI) Criteria Primary · Up to Day 116

Blood samples were collected for analysis of clinical chemistry parameters. Clinical concern ranges were \>=2x Upper Limit of Normal (ULN) units per liter (U/L) for alanine aminotransferase (ALT), \<30 millimoles per liter (mmol/L) for albumin, \>=2x ULN U/L for alkaline phosphatase, \>=2x ULN U/L for aspartate aminotransferase (AST), \<2 or \>2.75 mmol/L for Calcium, \>44.2 mmol/L for Creatinine, \<3 or \>9 mmol/L for Glucose, \<3 or\>5.5 mmol/L for Potassium, \<130 or \>150 mmol/L for Sodium, and \>=1.5xULN micromoles per liter for total bilirubin. Participants were counted in worst case cat

ALT; To Low

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	0

ALT; To Normal or No Change

Group	Value	95% CI
Placebo	18
GSK2982772 60 mg BID	22
GSK2982772 60 mg TID	24

ALT; To High

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	1
GSK2982772 60 mg TID	0

Albumin; To Low

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	0

Albumin; To Normal or No Change

Group	Value	95% CI
Placebo	18
GSK2982772 60 mg BID	23
GSK2982772 60 mg TID	24

Albumin; To High

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	0

Alkaline phosphatase; To Low

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	0

Alkaline phosphatase; To Normal or No Change

Group	Value	95% CI
Placebo	18
GSK2982772 60 mg BID	23
GSK2982772 60 mg TID	24

Number of Participants With Worst-case Post-Baseline Hematology Results by PCI Criteria Primary · Up to Day 116

Blood samples were collected for analysis of hematology parameters. Clinical concern ranges were \>0.54 calculated as proportion of red blood cells in blood for Hematocrit, \>180 grams per liter for Hemoglobin, \<0.8 x10\^9 cells per liter for Lymphocytes, \<1.5 x10\^9 cells per liter for Neutrophil count, \<100 or \>550 x10\^9 cells per liter for Platelet count and \<3 or \>20 x10\^9 cells per liter White Blood Cell count. Participants were counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose valu

Hematocrit; To Low

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	0

Hematocrit; To Normal or No Change

Group	Value	95% CI
Placebo	18
GSK2982772 60 mg BID	23
GSK2982772 60 mg TID	22

Hematocrit; To High

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	2

Hemoglobin; To Low

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	0

Hemoglobin; To Normal or No Change

Group	Value	95% CI
Placebo	17
GSK2982772 60 mg BID	23
GSK2982772 60 mg TID	23

Hemoglobin; To High

Group	Value	95% CI
Placebo	1
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	1

Lymphocytes; To Low

Group	Value	95% CI
Placebo	1
GSK2982772 60 mg BID	1
GSK2982772 60 mg TID	0

Lymphocytes; To Normal or No Change

Group	Value	95% CI
Placebo	17
GSK2982772 60 mg BID	22
GSK2982772 60 mg TID	24

Change From Baseline in Urine Potential of Hydrogen (pH) Primary · Baseline (Pre-dose on Day 1), Day 8, Day 15, Day 43, Day 85 and Follow-up (Day 116)

Urine samples were collected for measurement of urine pH at indicated time points. pH is a measure of hydrogen ion concentration and used to determine the acidity or alkalinity of urine. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Baseline is defined as the latest pre-dose assessment. Change from Baseline is defined as any post-dose visit value minus Baseline value.

DAY 8; n=18, 23, 22

Group	Value	95% CI
Placebo	0.69	± 0.788
GSK2982772 60 mg BID	-0.02	± 0.730
GSK2982772 60 mg TID	-0.11	± 0.786

DAY 15; n=17, 21, 22

Group	Value	95% CI
Placebo	0.56	± 0.609
GSK2982772 60 mg BID	0.14	± 0.673
GSK2982772 60 mg TID	-0.16	± 0.956

DAY 43; n=16, 21, 21

Group	Value	95% CI
Placebo	0.22	± 0.547
GSK2982772 60 mg BID	0.14	± 0.655
GSK2982772 60 mg TID	-0.36	± 1.108

DAY 85; n=14, 21, 22

Group	Value	95% CI
Placebo	0.29	± 0.975
GSK2982772 60 mg BID	0.00	± 0.592
GSK2982772 60 mg TID	-0.32	± 0.933

FOLLOW UP (Day 116); n=16, 22, 24

Group	Value	95% CI
Placebo	0.25	± 0.894
GSK2982772 60 mg BID	-0.07	± 0.541
GSK2982772 60 mg TID	-0.17	± 1.029

Change From Baseline in Urine Specific Gravity Primary · Baseline (Pre-dose on Day 1), Day 8, Day 15, Day 43, Day 85 and Follow-up (Day 116)

Urine samples were collected to analyze specific gravity of urine. Specific gravity, is a measure of urine concentration and is measured using a chemical test. Specific gravity measurements provide a comparison of the amount of substances dissolved in urine as compared to pure water. If there were no solutes present, the specific gravity of urine would be 1.000 the same as pure water. Specific gravity between 1.002 and 1.035 could be considered as normal. Baseline is defined as the latest pre-dose assessment. Change from Baseline is defined as any post-dose visit value minus Baseline value.

DAY 8; n=18, 23, 22

Group	Value	95% CI
Placebo	-0.0043	± 0.00765
GSK2982772 60 mg BID	-0.0020	± 0.00704
GSK2982772 60 mg TID	0.0014	± 0.00702

DAY 15; n=17, 21, 22

Group	Value	95% CI
Placebo	-0.0029	± 0.00679
GSK2982772 60 mg BID	-0.0028	± 0.00567
GSK2982772 60 mg TID	0.0022	± 0.00706

DAY 43; n=16, 21, 21

Group	Value	95% CI
Placebo	-0.0032	± 0.00692
GSK2982772 60 mg BID	0.0000	± 0.00649
GSK2982772 60 mg TID	0.0001	± 0.00694

DAY 85; n=14, 21, 22

Group	Value	95% CI
Placebo	0.0004	± 0.00560
GSK2982772 60 mg BID	-0.0022	± 0.00608
GSK2982772 60 mg TID	0.0022	± 0.00922

FOLLOW UP (Day 116); n=16, 22, 24

Group	Value	95% CI
Placebo	-0.0016	± 0.00719
GSK2982772 60 mg BID	-0.0020	± 0.00739
GSK2982772 60 mg TID	0.0032	± 0.00798

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Primary · Baseline (Pre-dose on Day 1), Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85 and Follow-up (Day 116)

Blood pressure was measured at indicated time points in supine or semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment. Change from Baseline is defined as any post-dose visit value minus Baseline value.

SBP; DAY 8; n=18, 23, 24

Group	Value	95% CI
Placebo	4.5	± 12.27
GSK2982772 60 mg BID	4.7	± 8.03
GSK2982772 60 mg TID	2.9	± 12.19

SBP; DAY 15; n=17, 22, 24

Group	Value	95% CI
Placebo	2.0	± 10.55
GSK2982772 60 mg BID	-1.0	± 8.91
GSK2982772 60 mg TID	-1.0	± 7.96

SBP; DAY 29; n=16, 22, 24

Group	Value	95% CI
Placebo	1.3	± 11.52
GSK2982772 60 mg BID	3.3	± 9.94
GSK2982772 60 mg TID	-1.3	± 13.26

SBP; DAY 43; n=16, 21, 23

Group	Value	95% CI
Placebo	-0.4	± 14.65
GSK2982772 60 mg BID	0.1	± 6.72
GSK2982772 60 mg TID	-2.2	± 10.51

SBP; DAY 57; n=14, 21, 22

Group	Value	95% CI
Placebo	-0.3	± 12.63
GSK2982772 60 mg BID	2.6	± 8.73
GSK2982772 60 mg TID	3.4	± 15.70

SBP; DAY 71; n=14, 21, 22

Group	Value	95% CI
Placebo	5.9	± 15.08
GSK2982772 60 mg BID	2.5	± 10.02
GSK2982772 60 mg TID	-1.0	± 12.95

SBP; DAY 85; n=14, 21, 22

Group	Value	95% CI
Placebo	4.4	± 10.36
GSK2982772 60 mg BID	2.9	± 9.52
GSK2982772 60 mg TID	-1.4	± 10.93

SBP; FOLLOW UP (Day 116); n=16, 22, 24

Group	Value	95% CI
Placebo	2.3	± 14.64
GSK2982772 60 mg BID	2.7	± 9.81
GSK2982772 60 mg TID	2.5	± 13.61

Change From Baseline in Heart Rate Primary · Baseline (Pre-dose on Day 1), Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85 and Follow-up (Day 116)

Heart rate was measured at indicated time points in supine or semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment. Change from Baseline is defined as any post-dose visit value minus Baseline value.

DAY 8; n=18, 23, 24

Group	Value	95% CI
Placebo	2.8	± 7.72
GSK2982772 60 mg BID	4.9	± 10.54
GSK2982772 60 mg TID	2.3	± 13.18

DAY 15; n=17, 22, 24

Group	Value	95% CI
Placebo	1.5	± 10.61
GSK2982772 60 mg BID	0.8	± 8.43
GSK2982772 60 mg TID	1.9	± 12.37

DAY 29; n=16, 22, 24

Group	Value	95% CI
Placebo	1.0	± 7.43
GSK2982772 60 mg BID	0.7	± 9.61
GSK2982772 60 mg TID	4.0	± 12.55

DAY 43; n=16, 21, 23

Group	Value	95% CI
Placebo	0.2	± 6.68
GSK2982772 60 mg BID	0.5	± 7.64
GSK2982772 60 mg TID	4.9	± 11.56

DAY 57; n=14, 21, 22

Group	Value	95% CI
Placebo	2.9	± 10.55
GSK2982772 60 mg BID	2.9	± 10.42
GSK2982772 60 mg TID	5.3	± 12.13

DAY 71; n=14, 21, 22

Group	Value	95% CI
Placebo	1.6	± 7.94
GSK2982772 60 mg BID	2.1	± 8.81
GSK2982772 60 mg TID	2.4	± 10.75

DAY 85; n=14, 21, 22

Group	Value	95% CI
Placebo	0.9	± 7.98
GSK2982772 60 mg BID	0.7	± 8.63
GSK2982772 60 mg TID	1.9	± 12.82

FOLLOW UP (Day 116); n=16, 22, 24

Group	Value	95% CI
Placebo	3.5	± 7.60
GSK2982772 60 mg BID	1.6	± 10.28
GSK2982772 60 mg TID	5.1	± 13.58

Change From Baseline in Respiratory Rate Primary · Baseline (Pre-dose on Day 1), Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85 and Follow-up (Day 116)

Respiratory rate was measured at indicated time points in supine or semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment. Change from Baseline is defined as any post-dose visit value minus Baseline value.

DAY 8; n=18, 23, 24

Group	Value	95% CI
Placebo	-0.8	± 2.18
GSK2982772 60 mg BID	-0.4	± 2.81
GSK2982772 60 mg TID	0.3	± 2.86

DAY 15; n=17, 22, 24

Group	Value	95% CI
Placebo	0.2	± 3.21
GSK2982772 60 mg BID	-0.6	± 2.44
GSK2982772 60 mg TID	-0.5	± 2.45

DAY 29; n=16, 22, 24

Group	Value	95% CI
Placebo	0.9	± 3.34
GSK2982772 60 mg BID	-0.8	± 3.38
GSK2982772 60 mg TID	0.0	± 4.01

DAY 43; n=16, 21, 23

Group	Value	95% CI
Placebo	-0.5	± 2.68
GSK2982772 60 mg BID	-0.4	± 3.06
GSK2982772 60 mg TID	0.3	± 3.50

DAY 57; n=14, 21, 22

Group	Value	95% CI
Placebo	0.3	± 3.12
GSK2982772 60 mg BID	-0.5	± 2.36
GSK2982772 60 mg TID	-0.3	± 3.08

DAY 71; n=14, 21, 22

Group	Value	95% CI
Placebo	0.2	± 3.09
GSK2982772 60 mg BID	-0.5	± 2.29
GSK2982772 60 mg TID	0.4	± 3.53

DAY 85; n=14, 21, 22

Group	Value	95% CI
Placebo	0.3	± 3.31
GSK2982772 60 mg BID	-0.5	± 2.89
GSK2982772 60 mg TID	-0.3	± 3.76

FOLLOW UP (Day 116); n=16, 22, 24

Group	Value	95% CI
Placebo	0.3	± 1.62
GSK2982772 60 mg BID	-0.1	± 2.60
GSK2982772 60 mg TID	-1.0	± 3.22

Change From Baseline in Body Temperature Primary · Baseline (Pre-dose on Day 1), Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85 and Follow-up (Day 116)

Body temperature was measured at indicated time points in supine or semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment. Change from Baseline is defined as any post-dose visit value minus Baseline value.

DAY 8; n=18, 23, 24

Group	Value	95% CI
Placebo	0.12	± 0.544
GSK2982772 60 mg BID	-0.11	± 0.365
GSK2982772 60 mg TID	0.03	± 0.656

DAY 15; n=17, 22, 24

Group	Value	95% CI
Placebo	0.09	± 0.466
GSK2982772 60 mg BID	-0.04	± 0.358
GSK2982772 60 mg TID	0.17	± 0.538

DAY 29; n=16, 22, 24

Group	Value	95% CI
Placebo	-0.07	± 0.447
GSK2982772 60 mg BID	-0.03	± 0.387
GSK2982772 60 mg TID	0.01	± 0.749

DAY 43; n=16, 21, 23

Group	Value	95% CI
Placebo	-0.14	± 0.358
GSK2982772 60 mg BID	-0.01	± 0.355
GSK2982772 60 mg TID	0.19	± 0.757

DAY 57; n=14, 21, 22

Group	Value	95% CI
Placebo	0.07	± 0.705
GSK2982772 60 mg BID	0.11	± 0.351
GSK2982772 60 mg TID	0.20	± 0.646

DAY 71; n=14, 21, 22

Group	Value	95% CI
Placebo	-0.01	± 0.487
GSK2982772 60 mg BID	-0.17	± 0.423
GSK2982772 60 mg TID	-0.07	± 0.667

DAY 85; n=14, 21, 22

Group	Value	95% CI
Placebo	0.06	± 0.483
GSK2982772 60 mg BID	-0.03	± 0.327
GSK2982772 60 mg TID	0.03	± 0.562

FOLLOW UP (Day 116); n=16, 22, 24

Group	Value	95% CI
Placebo	-0.05	± 0.459
GSK2982772 60 mg BID	0.02	± 0.505
GSK2982772 60 mg TID	0.07	± 0.624

Number of Participants With Any Time Post-Baseline Results for Electrocardiogram Findings Primary · Up to Day 116

Single 12-lead electrocardiograms were obtained at indicated time points during the study using an electrocardiogram machine that automatically calculates the heart rate and measures PR, QRS, QT, QT interval corrected for heart rate (QTc) using Bazett's formula (QTcB) intervals and QTc using Fridericia's formula (QTcF). The abnormal findings were categorized as clinically significant (CS) and not clinically significant (NCS). Baseline is defined as the latest pre-dose assessment. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless jud

Normal

Group	Value	95% CI
Placebo	7
GSK2982772 60 mg BID	8
GSK2982772 60 mg TID	7

Abnormal-NCS

Group	Value	95% CI
Placebo	11
GSK2982772 60 mg BID	15
GSK2982772 60 mg TID	17

Abnormal-CS

Group	Value	95% CI
Placebo	0
GSK2982772 60 mg BID	0
GSK2982772 60 mg TID	0

Plasma Concentrations of GSK2982772 at Days 43 and 85 Secondary · Day 43 (Pre-dose) and Day 85

Blood samples were collected for pharmacokinetic analysis of GSK2982772 following 60 mg BID and 60 mg TID dose at indicated time points. The pharmacokinetic analysis was performed using non-compartmental methods. The analysis was based on Pharmacokinetic Population which comprised of participants in the 'Safety' Population for whom a pharmacokinetic sample was obtained and analyzed.

Pre-dose on Day 43; n=20, 23

Group	Value	95% CI
GSK2982772 60 mg BID	16.905	± 11.1855
GSK2982772 60 mg TID	70.422	± 113.6397

Day 85; n=20, 22

Group	Value	95% CI
GSK2982772 60 mg BID	73.928	± 160.0059
GSK2982772 60 mg TID	82.694	± 152.4812

Post-dose Plasma Concentrations of GSK2982772 on Days 1 and 43 Secondary · 1, 2, 4 and 6 Hours Post-dose on Days 1 and 43

1 Hour Post-dose; Day 1; n=22, 24

Group	Value	95% CI
GSK2982772 60 mg BID	702.547	± 342.9405
GSK2982772 60 mg TID	681.675	± 293.8436

2 Hours Post-dose; Day 1; n=22, 24

Group	Value	95% CI
GSK2982772 60 mg BID	656.409	± 244.9217
GSK2982772 60 mg TID	664.417	± 198.8327

4 Hours Post-dose; Day 1; n=22, 24

Group	Value	95% CI
GSK2982772 60 mg BID	262.377	± 113.1955
GSK2982772 60 mg TID	249.583	± 86.0919

6 Hours Post-dose; Day 1; n=22, 24

Group	Value	95% CI
GSK2982772 60 mg BID	135.923	± 67.9503
GSK2982772 60 mg TID	176.567	± 194.8144

1 Hour Post-dose; Day 43; n=20, 23

Group	Value	95% CI
GSK2982772 60 mg BID	639.420	± 355.1716
GSK2982772 60 mg TID	858.261	± 391.7822

2 Hours Post-dose; Day 43; n=20, 23

Group	Value	95% CI
GSK2982772 60 mg BID	579.100	± 134.6629
GSK2982772 60 mg TID	690.652	± 187.1950

4 Hours Post-dose; Day 43; n=20, 23

Group	Value	95% CI
GSK2982772 60 mg BID	309.700	± 114.8441
GSK2982772 60 mg TID	304.348	± 136.1582

6 Hours Post-dose; Day 43; n=20, 23

Group	Value	95% CI
GSK2982772 60 mg BID	133.550	± 68.6742
GSK2982772 60 mg TID	154.809	± 124.4455

Adverse events — posted to ClinicalTrials.gov

Time frame: Serious adverse events (SAEs) and non-SAEs were collected from the start of study treatment until follow-up (up to Day 116). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 0/18 (0%)

Deaths: 0/18

GSK2982772 60 mg BID

Serious: 1/23 (4%)

Deaths: 1/23

GSK2982772 60 mg TID

Serious: 1/24 (4%)

Deaths: 0/24

Serious adverse events (2 terms)

Reaction	System	Placebo	GSK2982772 60 mg BID	GSK2982772 60 mg TID
Accidental overdose	Injury, poisoning and procedural complications	—	—	—
Procedural hypertension	Injury, poisoning and procedural complications	—	—	—

Other adverse events (17 terms — click to expand)

Reaction	System	Placebo	GSK2982772 60 mg BID	GSK2982772 60 mg TID
Headache	Nervous system disorders	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—
Fatigue	General disorders	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—
Dizziness	Nervous system disorders	—	—	—
Gastroenteritis	Infections and infestations	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Ligament sprain	Injury, poisoning and procedural complications	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—
Somnolence	Nervous system disorders	—	—	—
Tonsillitis	Infections and infestations	—	—	—
Type 2 diabetes mellitus	Metabolism and nutrition disorders	—	—	—

Most-reported serious reactions: Accidental overdose, Procedural hypertension.

Data from ClinicalTrials.gov NCT02776033 adverse events section.

Sponsor's own description

This is the first study with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with active plaque-type psoriasis (PsO). The primary objective will be to investigate the safety and tolerability of repeat oral doses of GSK2982772 60 milligram (mg) twice daily (BID) for 84 days in Cohort 1 and 60 mg thrice daily (TID) for 84 days in Cohort 2. In addition, a number of experimental and clinical endpoints will be employed to obtain information on the pharmacokinetics, pharmacodynamics, and efficacy in subjects with active PsO. There will be two Cohorts of subjects. In Cohort 1 after a screening period of up to 30 days, approximately 30 subjects will be randomized to receive either GSK2982772 60 mg BID or placebo for 84 days (12 Weeks), followed by a follow-up period (28 days). In Cohort 2 after a screening period of up to 30 days, approximately 24 subjects will be randomized to receive either GSK2982772 60 mg TID or placebo for 84 days (12 Weeks), followed by a follow-up period (28 days). The total duration of participation is approximately 20 Weeks from screening to the last study visit.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
Mifflin L, Ofengeim D, Yuan J. · · 2020 · cited 350× · PMID 32669658 · DOI 10.1038/s41573-020-0071-y
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease.
Nguyen TT, Wei S, Nguyen TH, Jo Y, et al · · 2023 · cited 221× · PMID 37612409 · DOI 10.1038/s12276-023-01046-5
Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes.
Pandeya A, Kanneganti TD. · · 2024 · cited 182× · PMID 37977994 · DOI 10.1016/j.molmed.2023.10.001
Small-molecule discovery through DNA-encoded libraries.
Peterson AA, Liu DR. · · 2023 · cited 145× · PMID 37328653 · DOI 10.1038/s41573-023-00713-6
Molecular Insights into the Mechanism of Necroptosis: The Necrosome As a Potential Therapeutic Target.
Chen J, Kos R, Garssen J, Redegeld F. · · 2019 · cited 135× · PMID 31766571 · DOI 10.3390/cells8121486
Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Weisel K, Scott NE, Tompson DJ, Votta BJ, et al · · 2017 · cited 99× · PMID 29226626 · DOI 10.1002/prp2.365
The role of necroptosis in disease and treatment.
Liu X, Xie X, Ren Y, Shao Z, et al · · 2021 · cited 75× · PMID 34977874 · DOI 10.1002/mco2.108
RIPK protein kinase family: Atypical lives of typical kinases.
Cuny GD, Degterev A. · · 2021 · cited 68× · PMID 32732131 · DOI 10.1016/j.semcdb.2020.06.014

Verify or expand the search:

Other trials of GSK2982772

Trials testing the same drug.

NCT04316585 — A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants · Phase 1 · completed
NCT03590613 — Phase I Study of GSK2982772 in Japanese Healthy Male Participants · Phase 1 · completed
NCT02903966 — GSK2982772 Study in Subjects With Ulcerative Colitis · Phase 2 · completed

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02776033 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 8 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02776033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02776033

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (2 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of GSK2982772

Other recruiting trials for Psoriasis

Other GlaxoSmithKline trials

Verify against primary sources